The effect of PI3K pathway inhibitor and chemical epigenetics in angiosarcoma cells

Research Project

Project/Area Number	16K19735
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Dermatology
Research Institution	Kyoto Prefectural University of Medicine
Principal Investigator	Wada Makoto 京都府立医科大学, 医学(系)研究科(研究院), 学内講師 (90733080)
Project Period (FY)	2016-04-01 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000) Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000) Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords	血管肉腫 / PI3K阻害剤 / HDAC阻害剤 / PI3K/mTOR阻害剤 / PI3K経路阻害剤 / エピジェネティクス制御化合物
Outline of Final Research Achievements	In this study, we evaluated the growth inhibition of PI3K inhibitor and epigenetics compounds in angiosarcoma cells. Histone deacetylase(HDAC) inhibitors suppressed the growth of angiosarcoma cells. HDAC inhibitors induced the cell-cycle arrest at G1 phase with the downregulated expression of cyclinD1 in ISOS-1 cells, and induced the cell-cycle arrest in G2/M phase with the upregulated expression of p21 in ISO-HAS cells. The combination of PI3K inhibitor and HDAC inhibitor additively suppressed the growth of angiosarcoma cells

Report

(3 results)